Company: OSRH
Filing Date: 2025-06-23
Form Type: 424B3
Source: 0001213900-25-056351
Chunk: 117

Company: OSR Holdings, Inc.
Filing Date: 2025-06-23
Form: 424B3
Chunk 117
---
’s
policies and procedures relating to transactions that may present conflicts of interest. Our officers and directors will be reimbursed
for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses
and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that
were made to our Sponsor, officers, directors, advisors or our or their affiliates. Any such payments prior to an initial business combination
will be made using funds held outside the Trust Account. Other than quarterly audit committee review of such payments, we do not expect
to have any additional controls in place governing our reimbursement payments to our directors and executive officers for their out-of-pocket expenses
incurred in connection with identifying and consummating an initial business combination.

During 2023, our Sponsor transferred 20,000 founder
shares to each of Drs. Chung, Reed and Roberts and Messrs. Euh and Park for their board service and Mr. Yoo for his service as chief
financial officer. Our Sponsor additionally transferred 20,000 private placement warrants to each of Dr. Reed for his service
as chairman of the board of directors, Dr. Chung for his service as chair of the audit committee, and Mr. Yoo for his service
as chief financial officer. No officer or director has received any compensation for services rendered to us during the year ended December 31,
2024.

Employment Agreements

We do not have an employment agreement with any
member of our management team.

Equity-Based Incentive Awards

As previously reported by the Company’s Current Report on Form 8-K dated February 14, 2025, the Company
held a special meeting of its stockholders on February 13, 2025 (the “February 13, 2025 Special Meeting”). At the February 13, 2025, Special Meeting, the Company’s stockholders approved the Company’s 2025 Omnibus Incentive Plan (“ Omnibus Plan”). A description of the material terms of the Omnibus Plan is set forth below. This summary is qualified in its entirety by reference to the complete text of the Omnibus Plan, a copy of which is attached as Exhibit 10.3to the registration statement of which this prospectus is part.

Outstanding Equity Awards at Fiscal Year End

None of our named officers had been granted options, or received any
other type of equity compensation, during the fiscal years ended December 31, 2024